

# Updates in the Management of ALS for Clinical Pharmacy Specialists: Treatment Considerations (Part 2)

## Resources and References

### Resources for Clinicians and Patients/Families

Searchlight Support Program for Radicava. Available at: <https://www.radicava.com/hcp/product-support-and-services/searchlight-support/>. Accessed on 6/7/19.

### References

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N Engl J Med*. 1994 Mar 3;330(9):585-91.

Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. *Neurology*. 1999 Sep 22;53(5):1059-63.

Miller RG. Review: riluzole increases 12-month survival in amyotrophic lateral sclerosis. ACP Journal Club. September/October 2009. Available at: <http://acpjic.acponline.org/Content/pdf/ACPJC-2000-133-2-054.pdf>. Accessed on 3/19/19.

Radicava (edaravone injection) [prescribing information]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation [2018]. 120785-W [08/2018] Iss. 08/18. Available at <https://www.radicava.com/assets/dist/pdfs/radicava-prescribing-information.pdf>. Accessed May 24, 2019.

Rilutek (riluzole) tablets [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2012. Iss. 04/16. Available at <https://medlibrary.org/lib/rx/meds/rilutek-3/>. Accessed May 24, 2019.

Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2017 Jul;16(7):505-512.